| Size | Price | |
|---|---|---|
| Other Sizes |
Purity: =98.51%
| Targets |
Biochemical reagent
Benzene-1,3,5-tricarboxylic acid does not have a defined pharmacological target. It is a chemical reagent used as a building block for metal-organic frameworks (MOFs) and other materials. Its mechanism of action is chemical: the three carboxylic acid groups can coordinate to metal ions to form extended structures, such as MOFs and coordination polymers. |
|---|---|
| ln Vitro |
1,3,5-Benzenetricarboxylic acid/trimesic acid is a natural product that has been reported in Phaseolus vulgaris.
Citric acid and trimesic acid reversibly reduced the activity of YopH enzyme and decreased the viability of Jurkat and macrophage cell lines. Importantly, these two compounds showed greater inhibitory properties against bacterial YopH activity than against human CD45 phosphatase activity. Molecular docking simulations confirmed that citric acid could bind to YopH phosphatase. Conclusion: Citric acid, a known antioxidant, can be considered an inhibitor of bacterial phosphatases.[2] Protein-protein interactions represent a new class of exciting but challenging drug targets, because their large, flat binding sites lack well-defined pockets for small molecules to bind. We report here a methodology for chemical synthesis and screening of large combinatorial libraries of bicyclic peptides displayed on rigid small-molecule scaffolds. With planar 1,3,5-Benzenetricarboxylic acid/trimesic acid as the scaffold, the resulting bicyclic peptides are effective for binding to protein surfaces such as the interfaces of protein-protein interactions. Screening of a bicyclic peptide library against tumor necrosis factor-α (TNFα) identified a potent antagonist that inhibits the TNFα-TNFα receptor interaction and protects cells from TNFα-induced cell death. Bicyclic peptides of this type may provide a general solution for inhibition of protein-protein interactions.[1] In vitro, benzene-1,3,5-tricarboxylic acid is used as a building block for the synthesis of metal-organic frameworks (MOFs) and other materials. As a tricarboxylic acid, it is a key ligand for the construction of porous materials with applications in gas storage, separation, and catalysis. |
| ln Vivo |
In vivo activity data for benzene-1,3,5-tricarboxylic acid are not available, as the compound is a chemical reagent used for materials science applications. It is not intended for in vivo administration and has no established in vivo pharmacokinetic or pharmacodynamic profile.
|
| Enzyme Assay |
In this study, researchers performed enzymatic activity assays of YopH phosphatase after treatment with citric acid in comparison with the inhibitory compound 1,3,5-Benzenetricarboxylic acid/trimesic acid, which has a similar structure. They also measured the cytotoxicity of these compounds in Jurkat T E6.1 and macrophage J774.2 cell lines. Researchers performed molecular docking analysis of the binding of citric acid molecules to YopH phosphatase.[2]
For in vitro synthesis of MOFs, benzene-1,3,5-tricarboxylic acid is used as a linker. Standard protocols involve reacting the acid with a metal salt (e.g., Cu(NO₃)₂, Zn(NO₃)₂) in a solvent under solvothermal conditions. The resulting MOF is characterized by XRD, BET, and SEM. |
| Cell Assay |
For in vitro cell-based experiments, benzene-1,3,5-tricarboxylic acid is not typically used directly in cell culture. It is a chemical reagent used for the synthesis of MOFs and other materials that may be subsequently tested in biological applications.
|
| Animal Protocol |
In vivo animal studies for benzene-1,3,5-tricarboxylic acid are not applicable, as the compound is a chemical reagent used for materials science. No animal studies have been conducted for this compound as a therapeutic agent.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of benzene-1,3,5-tricarboxylic acid are not available, as the compound is not a drug and is not administered to living organisms. The compound is a solid and should be stored under appropriate conditions.
|
| Toxicity/Toxicokinetics |
Benzene-1,3,5-tricarboxylic acid is a research chemical and should be handled with appropriate laboratory safety precautions. As a carboxylic acid, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications.
|
| References |
[1]. Screening bicyclic peptide libraries for protein-protein interaction inhibitors: Discovery of a tumor necrosis factor-α antagonist. J Am Chem Soc. 2013 Aug 14;135(32):11990-5.
[2]. Citric Acid Controls the Activity of YopH Bacterial Tyrosine Phosphatase. Drug Des Devel Ther. 2024 Apr 11:18:1165-1174. |
| Additional Infomation |
Benzene-1,3,5-tricarboxylic acid is a tricarboxylic acid formed by replacing the benzene ring with carboxyl groups at positions 1, 3, and 5. It is a tricarboxylic acid and a member of the benzoic acid family. It is the conjugate acid of benzene-1,3,5-tricarboxylic acid ester (1-). It has been reported that common bean (Phaseolus vulgaris) contains 1,3,5-benzenetricarboxylic acid, and relevant data are available for reference.
Benzene-1,3,5-tricarboxylic acid (Trimesic acid, CAS 554-95-0) is primarily a research-grade chemical reagent, not an FDA-approved pharmaceutical drug. Its primary application is as a building block for the synthesis of metal-organic frameworks (MOFs) and other coordination polymers. |
| Molecular Formula |
C9H6O6
|
|---|---|
| Molecular Weight |
210.14
|
| Exact Mass |
210.016
|
| CAS # |
554-95-0
|
| Related CAS # |
Benzene-1,3,5-tricarboxylic acid-d3;62790-27-6
|
| PubChem CID |
11138
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
561.4±45.0 °C at 760 mmHg
|
| Melting Point |
>300 °C(lit.)
|
| Flash Point |
307.4±25.2 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.663
|
| LogP |
1.51
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
15
|
| Complexity |
237
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C(C1C([H])=C(C(=O)O[H])C([H])=C(C(=O)O[H])C=1[H])=O
|
| InChi Key |
QMKYBPDZANOJGF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H6O6/c10-7(11)4-1-5(8(12)13)3-6(2-4)9(14)15/h1-3H,(H,10,11)(H,12,13)(H,14,15)
|
| Chemical Name |
benzene-1,3,5-tricarboxylic acid
|
| Synonyms |
Trimesic acid; NSC 3998; TMA; NSC-3998; benzene-1,3,5-tricarboxylic acid; 1,3,5-BENZENETRICARBOXYLIC ACID; Trimesinic acid; Trimesitinic acid; 5-Carboxyisophthalic acid; 1,3,5-Tricarboxybenzene;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (475.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.90 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7587 mL | 23.7937 mL | 47.5873 mL | |
| 5 mM | 0.9517 mL | 4.7587 mL | 9.5175 mL | |
| 10 mM | 0.4759 mL | 2.3794 mL | 4.7587 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA